Strategic Investment
Zydus Lifesciences Forms 50:50 Joint Venture with Sunshine Healthcare to Expand Pharmaceutical Manufacturing in Sri Lanka
NSE
zyduslife
BSE
532321
Zydus Lifesciences has entered into a Share Subscription and Shareholders’ Agreement with Sunshine Healthcare Lanka Limited to acquire a 50% stake in Zydus Sunshine Lifesciences (Private) Limited. The joint venture will establish a pharmaceutical manufacturing facility in Sri Lanka to strengthen domestic production and reduce dependence on imported medicines.
PRICE-SENSITIVE TRIGGER
Event: Formation of a 50:50 pharmaceutical manufacturing joint venture in Sri Lanka.
Type: Strategic Investment / Joint Venture
Impact: Positive
Immediate Effect:Â The agreement establishes Zydus Sunshine Lifesciences as a 50:50 joint venture between Zydus Lifesciences and Sunshine Healthcare. The project marks the commencement of a new pharmaceutical manufacturing facility in Sri Lanka, subject to completion of the share subscription.
Key Metrics:
- Investment by Zydus under share subscription:Â Up to USD 5 million
- Equity stake acquired:Â 50%
- Ownership structure:Â 50:50 Joint Venture
- Overall project investment commitment:Â More than USD 20 million
- Manufacturing facility location:Â Horana Export Processing Zone, Sri Lanka
- Target company turnover:Â Nil (recently incorporated)
Highlight:
- Investment Commitment: Overall project investment exceeds USD 20 million to establish a pharmaceutical manufacturing facility in Sri Lanka.
What Happened ?
Zydus Lifesciences has signed a Share Subscription and Shareholders’ Agreement with Sunshine Healthcare Lanka Limited and Zydus Sunshine Lifesciences (Private) Limited to subscribe to 50% of the paid-up equity capital of the newly incorporated company.
Upon completion of the subscription, Zydus Sunshine will operate as a jointly controlled entity focused on manufacturing pharmaceutical products in Sri Lanka. The project supports the country’s efforts to strengthen domestic pharmaceutical production, improve medicine availability and reduce reliance on imports.
The manufacturing facility will be developed on nearly four acres within the Board of Investment’s Horana Export Processing Zone.
Key Details
Transaction Highlights:
- Zydus will subscribe to 50% of Zydus Sunshine’s paid-up equity capital.
- Consideration will be entirely in cash.
- Subscription is expected to be completed within 90 working days from execution of the agreement.
- The target company was incorporated on May 30, 2026.
- The company currently has no turnover as operations are yet to commence.
- The joint venture will manufacture pharmaceutical products primarily for the Sri Lankan market.
- The project aims to improve medicine affordability, supply security and local manufacturing capability.
- Technology transfer and local employment generation form key objectives of the partnership.
Governance Structure:
- Six-member Board of Directors.
- Three directors nominated by Zydus.
- Three directors nominated by Sunshine Healthcare.
- Chairperson to be nominated by Zydus with a casting vote except on reserved matters.
- Changes to capital structure require approval from both partners.
Note:
- The transaction is not classified as a related-party transaction and no promoter group entity has any interest in the acquisition.
Risk Analysis
Summary:
- The strategic rationale is strong; however, commercial success depends on successful project execution, regulatory compliance and timely commissioning of the manufacturing facility.
Key Risks:
- Completion of share subscription within the expected timeline.
- Greenfield manufacturing execution risk.
- Regulatory approvals and ongoing compliance in Sri Lanka.
- Demand ramp-up for locally manufactured pharmaceutical products.
- Capital deployment and operational execution during project development.
Worst Case:
- Delays in construction, approvals or operational ramp-up could postpone revenue generation and reduce expected returns on investment.
Risk Level: Medium
Company Commentary
- The partnership combines Zydus’ global pharmaceutical manufacturing expertise with Sunshine Healthcare’s strong local distribution network.
- The project is intended to strengthen Sri Lanka’s healthcare ecosystem through increased domestic pharmaceutical manufacturing.
- Management believes local manufacturing will improve medicine accessibility, affordability and supply chain resilience.
- The initiative is also expected to facilitate technology transfer and create skilled employment opportunities in Sri Lanka.
Official Exchange Filing: Zydus Lifesciences Limited
